文献速递系统性红斑狼疮

乌司奴单抗治疗活动性系统性红斑狼疮一年疗效与安全性维持:II期随机双盲安慰剂对照交叉试验

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2020-04-01

这项II期多中心随机双盲安慰剂对照交叉试验纳入102例活动性SLE患者,评估乌司奴单抗联合标准治疗的疗效与安全性。第24周时乌司奴单抗组SRI-4应答率显著高于安慰剂组(62% vs 33%,P=0.006),且应答维持至第48周(63.3%)。安全性与其他适应症一致,未观察到死亡、恶性肿瘤、机会性感染或结核。

要点

  • 乌司奴单抗组第24周SRI-4应答率62%,显著高于安慰剂组33%(P=0.006)。
  • 乌司奴单抗组SRI-4应答维持至第48周,应答率63.3%。
  • 全部乌司奴单抗治疗患者至第56周,81.7%发生至少1例不良事件,15.1%发生至少1例严重不良事件。

核心结论

  • 乌司奴单抗在活动性SLE患者中提供持续至1年的临床获益,安全性特征与其他适应症一致。

研究设计与样本

  • II期多中心、前瞻性、随机、双盲、安慰剂对照交叉试验,纳入102例活动性SLE患者。
  • 患者按3:2随机接受乌司奴单抗(第0周单次静脉输注约6 mg/kg,第8周起每8周皮下注射90 mg)或安慰剂联合标准治疗。
  • 第24周安慰剂组交叉接受每8周皮下注射90 mg乌司奴单抗,原乌司奴单抗组继续治疗至第40周。

主要发现

  • 第24周主要终点分析中,乌司奴单抗组SRI-4应答率62%,安慰剂组33%,差异显著(P=0.006)。
  • 乌司奴单抗组SRI-4应答维持至第48周,应答率63.3%。
  • 乌司奴单抗组其他疾病活动指标的应答率同样维持至第48周。
  • 安慰剂组交叉至乌司奴单抗治疗的患者(n=33)各项疗效指标应答率均有所提高。
  • 全部乌司奴单抗治疗患者至第56周,81.7%发生至少1例不良事件,15.1%发生至少1例严重不良事件;未观察到死亡、恶性肿瘤、机会性感染或结核病例。

关键数值与推荐

  • 活动性SLE定义:SLEDAI-2K评分≥6,且筛选时至少1个BILAG A器官域评分和/或至少2个BILAG B器官域评分。
  • 主要终点为第24周SRI-4应答率:乌司奴单抗组62% vs 安慰剂组33%(P=0.006)。
  • 第48周乌司奴单抗组SRI-4应答率为63.3%。

临床怎么用

  • 对于标准治疗下仍活动(SLEDAI-2K≥6且BILAG符合条件)的SLE患者,乌司奴单抗联合标准治疗可考虑作为治疗选择。
  • 乌司奴单抗治疗应答可持续至1年,安全性与其他适应症一致。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of ustekinumab through 1 year in a phase II trial in patients with systemic lupus erythematosus (SLE). METHODS: Eligible patients were diagnosed as having clinically active SLE (based on Systemic Lupus International Collaborating Clinics criteria), despite standard background therapy. Active disease was defined by an SLE Disease Activity Index 2000 (SLEDAI-2K) score of ≥6 as well as having ≥1 British Isles Lupus Assessment Group (BILAG) A organ domain score and/or ≥2 BILAG B organ domain scores present at screening. Patients (n = 102) were randomized (3:2) to receive either ustekinumab (~6 mg/kg of single intravenous infusion at week 0, then 90-mg subcutaneous injections every 8 weeks beginning at week 8) or a matching placebo added to standard therapy. At week 24, the placebo group crossed over to receive a subcutaneous 90-mg dose of ustekinumab every 8 weeks, and the original ustekinumab group continued to receive therapy through week 40. Maintenance of efficacy was assessed using the SLEDAI-2K, the SLE Responder Index 4 (SRI-4), physician global assessment, and mucocutaneous and joint disease measures in a modified intent-to-treat population. RESULTS: SRI-4 response rates were significantly greater in the ustekinumab group (62%) versus the placebo group (33%) in the week 24 primary end point analysis (P = 0.006) and were maintained at week 48 (63.3%) in the ustekinumab group. In the ustekinumab group, response rates across other disease measures were also maintained through week 48. Among patients in the placebo group who crossed over to ustekinumab treatment (n = 33), increased response rates across efficacy measures were noted. Among all ustekinumab-treated patients, 81.7% had ≥1 adverse event (AE), and 15.1% had ≥1 serious AE through week 56. No deaths, malignancies, opportunistic infections, or tuberculosis cases were observed. CONCLUSION: Ustekinumab provided sustained clinical benefit in patients with SLE through 1 year, with a safety profile consistent with other indications.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020. PMID: 31769212. doi:10.1002/art.41179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。